|
Overall Morningstar
Rating™ |
| What is this? |
 |
 |
| As of 2009-10-31 |
|
Out of
Health Funds |
|
| Rating derived from a weighted average of the fund's 3, 5, 10-year rating which are based on risk-adjusted performance. |
|
|
|
Morningstar®
Style Box™ |
| What is this? |
|
 |
|
Large |
|
|
Blend |
|
|
|
|
|
|
|
|
| As of
2009-06-30 |
|
|
| Day Change |
| $ 0.06 |
|
|
| NAV (2009-11-20) |
| $ 18.47 |
|
|
| YTD Return % (2009-11-20) |
| 21.27% |
|
|
| Total Assets ($ mil) |
| 25 |
|
| Growth of $10,000 |
 |
Fund: |
Kinetics Medical No Load |
| (from
1999-10-01
to 2009-10-31) |
 |
Category: |
Health |
|
 |
Index: |
S&P 500 TR |
| Total Annualized Returns % |
1yr, 3yr and 5yr Returns as of 2009-11-20 |
| Inception date: 1999-10-01 |
10yr and Inception Returns as of 2009-10-31 |
|
YTD Returns as of 2009-11-20 |
|
|
YTD |
1 Year |
3 Year |
5 Year |
10 Year |
Since Inception |
| Fund |
21.27 |
40.65 |
3.58 |
6.51 |
6.94 |
7.39 |
| +/- Category |
11.22 |
31.90 |
6.20 |
3.37 |
1.08 |
--- |
| +/- S&P 500 TR |
-2.25 |
-8.15 |
9.48 |
5.83 |
--- |
--- |
|
|
| Standardized Annual Returns % more on standardized returns |
| Quarter-End (as of
2009-09-30) |
24.95 |
6.25 |
6.19 |
7.05 |
--- |
8.26 |
| Month-End (as of 2009-10-31) |
15.96 |
17.17 |
2.52 |
5.81 |
6.94 |
7.39 |
|
|
| After Tax Returns % (as of
2009-09-30
)
|
| On Distribution |
--- |
15.98 |
1.56 |
5.21 |
6.61 |
--- |
| On Distribution & Sale of Shares |
--- |
11.24 |
1.88 |
4.83 |
6.01 |
--- |
|
|
| Morningstar Rating |
--- |
--- |
 |
 |
 |
--- |
|
| # of compared funds covered (3 yrs : out of 151 funds), (5 yrs : out of 143 funds), (10 yrs : out of 60 funds). Ratings are based on risk-adjusted performance. The maximum initial sales fee is
none,
the maximum deferred sales fee is
none,
and the maximum redemption sales fee is
2.00%.
|
|
| The performance quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate thus an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted herein. |
|
|
|
|
| Sector Breakdown % |
|
 |
Information |
0.00 |
 |
Software |
0.00 |
 |
Hardware |
0.00 |
 |
Media |
0.00 |
 |
Telecommunications |
0.00 |
|
|
|
 |
Service |
100.00 |
 |
Healthcare |
98.02 |
 |
Consumer Services |
0.00 |
 |
Business Services |
1.98 |
 |
Financial Services |
0.00 |
|
|
|
 |
Manufacturing |
0.00 |
 |
Consumer Goods |
0.00 |
 |
Industrial Materials |
0.00 |
 |
Energy |
0.00 |
 |
Utilities |
0.00 |
|
|
|
|
| |
|
|
| Asset Allocation |
|
 |
|
| % of Net Assets |
 |
Cash |
3.2 |
 |
Stocks |
96.8 |
|
Bonds |
0.0 |
 |
Other |
0.0 |
|
|
|
Foreign Stocks |
33.0 |
|
(as a % of Assets) |
|
|
| Data through 2009-06-30 |
Data through 2009-06-30 |
 |
| Holding Status |
|
| Total Number of Stock Holdings |
45 |
|
Turnover % |
13 |
| Total Number of Bond Holdings |
0 |
|
30 Day SEC Yield % |
--- |
| % of Assets in Top 10 Holdings |
58.01 |
|
ending as of
2009-09-30 |
|
|
|
|
View Data Definitions |
| Top 10 Holdings |
Sector |
P/E |
YTD
Return % |
% of Net
Assets |
|
|
|
|
|
|
|
Biogen Idec, Inc. |
|
17.99 |
-2.62 |
6.84 |
|
Johnson & Johnson |
|
13.09 |
7.37 |
6.76 |
|
Life Technologies Corp |
|
80.65 |
112.27 |
6.48 |
|
Lonza Grp |
|
--- |
--- |
6.17 |
|
Novartis AG ADR |
|
13.99 |
10.23 |
6.13 |
|
 |
|
GlaxoSmithKline PLC ADR |
|
14.71 |
16.41 |
5.80 |
|
Genzyme Corporation |
|
44.25 |
-24.59 |
5.63 |
|
Eli Lilly & Company |
|
--- |
-4.27 |
5.20 |
 |
Abbott Laboratories |
|
17.61 |
3.43 |
4.63 |
|
China Pharmaceutical Group, Ltd. |
|
3.17 |
137.76 |
4.37 |
|
|
 |
Data through 2009-06-30 |
|
| YTD Return through 2009-11-20 |
|
|
| Fund Inception: 1999-10-01 |
|
Portfolio Manager (Start Date) |
|
|
|
|
|
Bruce P. Abel (2001-12-31) |
|
|
|
Abel is a portfolio manager with Kinetics Asset Management, his employer since 1999. Prior to joining the firm, he was employed with Brookhaven National Laboratory since 1989 where he worked researching, developing and implementing technical and scientific programs and systems in the areas of nuclear physics and computer programming, and industrial design. He has over 10 years experience in the fields of science, chemistry, physics, and engineering. |
|
|
|
|
|
Peter B. Doyle (1999-10-01) |
|
|
|
Doyle is the Chief Investment Strategist for Kinetics Asset Management and the founder of both Kinetics Asset Management and Horizon Asset Management. |
|
|
|
|
|
Murray Stahl (2001-04-30) |
|
|
|
Stahl is the chairman, treasurer and co-founder of Horizon since 1994. |
|
|
|
|
|
Steven Tuen (2001-04-30) |
|
|
|
Tuen is a portfolio manager with Kinetics Asset Management, his employer since 1999. Previously, he was an analyst and director of research with IPO Value Monitor from 1996 to 1999. Prior to that, from 1989 to 1996, he was an analyst at Bankers Trust Company where he became a portfolio manager of the private banking group.
Tuen holds the Chartered Financial Analyst designation. |
|
|
|
|
|
Paul Mampilly (2007-05-01) |
|
|
|
Mampilly provides substantial input on research, stock selection and portfolio composition. Mampilly joined the Investment Adviser in 2006 and has over fifteen years experience as an investment professional. From January 2002 through May 2003, he held employment with ING Funds as a senior research analyst and healthcare group head, responsible for managing a team of analysts covering healthcare related companies of all market capitalizations. |
|
|
|
|
|
David Kingsley (2009-08-07) |
|
|
|
Kingsley has also served as a portfolio manager at Horizon since July 2006. Prior to Horizon, he was a portfolio manager at Kingsley Capital Management, LLC from 2001 through 2005. |
|
|
|
|
Sales Charge %
(taken from prospectus dated 2009-04-30) |
| Front: |
None |
| Deferred: |
None |
|
| Expense Ratio % |
1.41 |
based on net assets
(taken from annual report dated 2008-12-31)
|
|
| Correspondence Information |
555 Taxter Road
Suite 175
Elmsford,
NY
10523
USA |
|
|
|
|
|
